In this regard, very recently, it has been proven that ADRN-to-MES reprogrammed NB cells can escape from ALK targeted therapy, disclosing that NB cancer cells with an undifferentiated phenotype can mediate resistance to ALK inhibitors [101]. This evidence concerns the gene ALK and neuroblastoma.